Bryn Pharma
Bryn Pharma is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Bryn Pharma.
Bryn Pharma is a company.
Key people at Bryn Pharma.
Bryn Pharma is a clinical-stage pharmaceutical company developing a needle-free epinephrine nasal spray for emergency treatment of anaphylaxis, targeting patients with severe allergies who struggle with traditional injectors.[1][2][6] Formerly known as Epi-Now, the company serves individuals at risk of life-threatening allergic reactions, addressing key problems like needle phobia, ease of use, portability, and affordability in epinephrine delivery.[1][2] Founded in 2016 (with some sources noting 2017), it has raised $125.2M in funding, reaching Series E stage, with its latest round of $26.72M about a year ago, signaling strong growth momentum toward commercialization.[1][3]
Headquartered in Raleigh, North Carolina, Bryn Pharma has demonstrated product viability through studies showing efficacy even with nasal congestion and holds 10 patents, including on epinephrine spray formulations.[1]
Bryn Pharma emerged from a patient-driven mission to improve anaphylaxis management, founded in 2016 as Epi-Now by individuals motivated by personal experiences with allergies—explicitly "founded by patients for patients."[1][2] The idea stemmed from decades-old limitations in epinephrine autoinjectors, prompting development of a nasal spray alternative using advanced science and patented technologies.[2]
Early traction included pharmacokinetic studies published around 2020 and patent grants, such as one in 2023 for epinephrine spray formulations related to allergology and sympathetic nervous systems.[1][4] Key leadership hires, like a former COO from Aerami Therapeutics, bolstered clinical and regulatory progress for its lead asset, NDS1C.[2] Investors like Blue Cloud Ventures supported its evolution to Series E.[1]
Bryn Pharma rides the wave of innovative drug delivery in allergy care, capitalizing on rising anaphylaxis prevalence amid growing food allergy awareness and demand for user-friendly alternatives to EpiPens.[1][2] Timing aligns with recent FDA nods to nasal epinephrine options, filling unmet needs in a large, expanding market stagnant for decades.[2]
Market forces like patient non-adherence to injectors (due to complexity and phobia) favor its approach, while its inhaled platform hints at broader applications beyond anaphylaxis.[5] By prioritizing accessibility, it influences pharma ecosystems, potentially lowering barriers for at-risk populations and spurring competition in acute care delivery.[2]
Bryn Pharma nears pivotal regulatory milestones for NDS1C approval, with a planned event in June 2025 signaling commercialization push amid strong funding and clinical wins.[1][5] Trends like personalized medtech and needle-free pharma will propel it, especially as allergy cases surge globally.
Its influence could expand via platform tech into other injectables, solidifying disruption in emergency care—transforming a patient-founded idea into a market standard for those seconds from crisis.[2][5]
Key people at Bryn Pharma.
